Background: Lupus nephritis (LN) is a common and severe organ involvement manifesting itself in systemic lupus erythematosus (SLE). There is a considerable difference in prevalence, severity, treatment response and outcomes between Asian LN patients and LN patients from other racial backgrounds. Summary: Asian SLE patients have a higher prevalence of LN than Caucasian SLE patients and often present with a more severe disease. Increasing data from genetic studies, accompanied by progress in high-throughput genotyping, have advanced our knowledge about genetic predispositions that might partly contribute to the clinical variations observed. Corticosteroids combined with either cyclophosphamide (CYC) or mycophenolic acid (MPA) is the current standard-of-care induction regimen for severe LN irrespective of race or ethnicity. However, the preference for MPA or CYC, and possibly the optimum dose for MPA, is influenced by the patient's origin. Also, there is an insufficient evidence base for reduced-dose intravenous CYC in Asian patients. Health economics and access to prompt diagnosis and treatment are still challenging issues in some Asian regions. The former represents a significant obstacle limiting the access of patients to MPA despite the proven efficacy of the drug as an induction agent and its superiority over azathioprine (AZA) in preventing disease flares when used for long-term maintenance immunosuppression. Calcineurin inhibitors such as tacrolimus deserve further investigation in view of their additional effect on podocytes by reducing proteinuria and the promising data from Asian patients. Despite considerable advances in the clinical management of LN over the past few decades with resultant improvements in patients' outcomes, there are still knowledge gaps and unmet clinical needs. Asia has made substantial contributions to the evidence base that guides clinical management and continues to offer invaluable opportunities for research pursuits. Key Messages: Treatment responses and clinical outcomes in Asian patients with LN compare favorably with patients from other parts of the world. The prevention and treatment of infective complications remain significant challenges in managing LN in Asia. Facts from East and West: (1) The prevalence of SLE is lower among Caucasians than other ethnicities. A higher prevalence is observed among Asians and African Americans, while the highest prevalence is found in Caribbean people. The prevalence of LN in Asian SLE patients is much higher than in Caucasians as well. However, the 10-year renal outcome and renal survival rate appear to be better in Asians. (2) Polymorphisms of genes involved in the immune response, such as Fcγ receptor, integrin alpha M, TNF superfamily 4, myotubularin-related protein 3 and many others, might be partly responsible for the differences in prevalence between the different ethnic groups. European ancestry was shown to be associated with a decrease in the risk of LN even after adjustment for genes most associated with renal disease. (3) Access to health care is a key determinant of disease progression, treatment outcome and the management of complications such as infections, particularly in South Asia, and might also explain disparities between clinical outcomes. (4) The efficacy of low-dose CYC combined with corticosteroids for induction treatment of LN was proved in European Caucasian patients. This treatment is also used in Asia, although no formal evaluation of efficacy and safety in comparison with other treatment regimens exists in this population. The efficacy of mycophenolate mofetil (MMF) is similar to that of CYC, and similar between Asians and Caucasians. MMF may be more effective than CYC in inducing response in high-risk populations such as African American or Hispanic patients. MMF might cause less infection-related events in Asians, but its high cost prevents broader usage at present. (5) For maintenance therapy, corticosteroid combined with AZA or MMF is used worldwide, with a broadly similar efficacy of both treatments, although there are data suggesting that in high-risk populations (e.g. African Americans) MMF may be more effective in preventing renal flares. AZA is often preferred in Asia due to economic constraints and because of its safety in pregnancy. (6) Alternative therapies under investigation include rituximab, which might be more efficient in Caucasians, as well as belimumab. Recent Japanese and Chinese studies have indicated a potential benefit of tacrolimus as a substitute for or in addition to CYC or MMF (dual or triple immunosuppression). Mizoribine is used in Japan exclusively.

Keywords:
Asians, Azathioprine, Cyclophosphamide, Lupus nephritis, Mycophenolate
1.
Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N: Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012;64:159-168.
2.
Seligman VA, Lum RF, Olson JL, Li H, Criswell LA: Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002;112:726-729.
3.
Osio-Salido E, Manapat-Reyes H: Epidemiology of systemic lupus erythematosus in Asia. Lupus 2010;19:1365-1373.
4.
Yap DY, Tang CS, Ma MK, Lam MF, Chan TM: Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3248-3254.
5.
Boey ML, Peebles CL, Tsay G, Feng PH, Tan EM: Clinical and autoantibody correlations in Orientals with systemic lupus erythematosus. Ann Rheum Dis 1988;47:918-923.
6.
Shayakul C, Ong-aj-yooth L, Chirawong P, Nimmannit S, Parichatikanond P, Laohapand T, et al: Lupus nephritis in Thailand: clinicopathologic findings and outcome in 569 patients. Am J Kidney Dis 1995;26:300-307.
7.
Lee SS, Li CS, Li PC: Clinical profile of Chinese patients with systemic lupus erythematosus. Lupus 1993;2:105-109.
8.
Kaslow RA: High rate of death caused by systemic lupus erythematosus among US residents of Asian descent. Arthritis Rheum 1982;25:414-418.
9.
Samanta A, Feehally J, Roy S, Nichol FE, Sheldon PJ, Walls J: High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann Rheum Dis 1991;50:490-492.
10.
Fatemi A, Kazemi M, Sayedbonakdar Z, Farajzadegan Z, Karimzadeh H, Moosavi M: Long-term outcome of biopsy-proven lupus nephritis in Iran. Int J Rheum Dis 2013;16:739-746.
11.
Kono M, Yasuda S, Kato M, Kanetsuka Y, Kurita T, Fujieda Y, et al: Long-term outcome in Japanese patients with lupus nephritis. Lupus 2014;23:1124-1132.
12.
Korbet SM, Schwartz MM, Evans J, Lewis EJ: Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-254.
13.
Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C: The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007;22:2531-2539.
14.
Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Nardi N, et al: Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. Medicine (Baltimore) 2010;89:300-307.
15.
Dhir V, Aggarwal A, Lawrence A, Agarwal V, Misra R: Long-term outcome of lupus nephritis in Asian Indians. Arthritis Care Res (Hoboken) 2012;64:713-720.
16.
Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-64.
17.
Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, et al: Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69:1846-1851.
18.
Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-1162.
19.
Chan TM, Tse KC, Tang CS, Lai KN, Li FK: Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-272.
20.
Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al: Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005;10:504-510.
21.
Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al: Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012;27:1467-1472.
22.
Li LH, Yuan H, Pan HF, Li WX, Li XP, Ye DQ: Role of the Fcγ receptor IIIA-V/F158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Scand J Rheumatol 2010;39:148-154.
23.
Lee YH, Ji JD, Song GG: Fcγ receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Lupus 2009;18:727-734.
24.
Fan Y, Li LH, Pan HF, Tao JH, Sun ZQ, Ye DQ: Association of ITGAM polymorphism with systemic lupus erythematosus: a meta-analysis. J Eur Acad Dermatol Venereol 2011;25:271-275.
25.
Yang W, Zhao M, Hirankarn N, Lau CS, Mok CC, Chan TM, et al: ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. Hum Mol Gen 2009;18:2063-2070.
26.
Zhou XJ, Cheng FJ, Qi YY, Zhao MH, Zhang H: A replication study from Chinese supports association between lupus-risk allele in TNFSF4 and renal disorder. Biomed Res Int 2013;2013:597921.
27.
Zhou XJ, Nath SK, Qi YY, Cheng FJ, Yang HZ, Zhang Y, et al: Brief report: identification of MTMR3 as a novel susceptibility gene for lupus nephritis in northern Han Chinese by shared-gene analysis with IgA nephropathy. Arthritis Rheumatol 2014;66:2842-2848.
28.
Parsa A, Lovett DH, Peden EA, Zhu L, Seldin MF, Criswell LA: Renin-angiotensin system gene polymorphisms predict the progression to renal insufficiency among Asians with lupus nephritis. Genes Immun 2005;6:217-224.
29.
Chan TM: Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2015;11:46-61.
30.
Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619.
31.
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-1112.
32.
Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al: Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010;49:128-140.
33.
Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-2131.
34.
Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK: Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995;71:321-327.
35.
Mok CC, Ho CT, Chan KW, Lau CS, Wong RW: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002;46:1003-1013.
36.
Weng MY, Weng CT, Liu MF: The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol 2010;29:771-775.
37.
Koo HS, Kim YC, Lee SW, Kim DK, Oh KH, Joo KW, et al: The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus 2011;20:1442-1449.
38.
Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, et al: Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton) 2014;19:11-20.
39.
Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797-808.
40.
Chan TM, Tse KC, Tang CS, Mok MY, Li FK: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-1084.
41.
Yap DY, Ma MK, Mok MM, Tang CS, Chan TM: Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 2013;52:480-486.
42.
Mak SK, Lo KY, Lo MW, Chan SF, Tong GM, Wong PN, et al.: Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology (Carlton) 2008;13:331-336.
43.
Hardinger KL, Hebbar S, Bloomer T, Murillo D: Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs mycophenolate mofetil. Clin Transplant 2008;22:555-561.
44.
Traitanon O, Avihingsanon Y, Kittikovit V, Townamchai N, Kanjanabuch T, Praditpornsilpa K, et al: Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus 2008;17:744-751.
45.
Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al: Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50:2559-2568.
46.
Tse KC, Tang CS, Lam MF, Yap DY, Chan TM: Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 2009;36:76-81.
47.
Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guidelines for Glomerulonephritis. Kidney Int Suppl (2011) 2012;2:139-274.
48.
Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al: Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 2012;17:352-357.
49.
Mok CC, Ying KY, Lau CS, Yim CW, Ng WL, Wong WS, et al: Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004;43:269-276.
50.
Yap DY, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM: Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology (Oxford) 2014;53:2232-2237.
51.
Zavada J, Pesickova S, Rysava R, Olejarova M, Horak P, Hrncir Z, et al: Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 2010;19:1281-1289.
52.
Kamijo Y, Hashimoto K, Takahashi K, Ehara T, Shigematsu H, Higuchi M: Treatment with cyclosporine A improves SLE disease activity of Japanese patients with diffuse proliferative lupus nephritis. Clin Nephrol 2011;76:136-143.
53.
Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, et al: Long-term treatment of lupus nephritis with cyclosporin A. QJM 1998;91:573-580.
54.
Tanaka H, Oki E, Tsuruga K, Yashiro T, Hanada I, Ito E: Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. Clin Nephrol 2009;72:430-436.
55.
Tanaka H, Oki E, Tsugawa K, Nonaka K, Suzuki K, Ito E: Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study. Lupus 2007;16:896-900.
56.
Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al: Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-244.
57.
Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS: Successful treatment of class V + IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008;19:2001-2010.
58.
Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al: Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18-26.
59.
Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, et al: Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 2014, Epub ahead of print.
60.
Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E: Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol 2008;27:85-89.
61.
Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T, et al: Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol 2005;64:28-34.
62.
Tanaka H, Aizawa T, Watanabe S, Oki E, Tsuruga K, Imaizumi T: Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus 2014;23:813-818.
63.
Fuke T, Abe Y, Hibino S, Takeshi M, Saito T, Sakurai S, et al: Mizoribine requires individual dosing due to variation of bioavailability. Pediatr Int 2012;54:885-891.
64.
Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, et al: Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008;17:638-644.
65.
Yap DY, Ma MK, Tang CS, Chan TM: Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrology (Carlton) 2012;17:676-680.
66.
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-1226.
67.
Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al: Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379-389.
68.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-3930.
69.
Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-731.
70.
Dooley M, Houssiau F, Aranow C, D'Cruz D, Askanase A, Roth D, et al: Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72.
71.
Feng PH: Systemic lupus erythematosus: the face of Asia. Ann NY Acad Sci 2007;1108:114-120.
72.
Sircar D, Sircar G, Waikhom R, Raychowdhury A, Pandey R: Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India. Indian J Nephrol 2013;23:5-11.
73.
Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S, Avihingsanon Y: Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 2010;78:389-395.
74.
Kittanamongkolchai W, Rukrung C, Supasiri T, Lertjirachai I, Somparn P, Chariyavilaskul P, et al: Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. Lupus 2013;22:727-732.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.